Cytoskeleton, Inc. is a leading CRO leveraging 30+ years of cytoskeletal and signal transduction biology expertise to offer high-quality drug screening, MOA studies, and target validation. Powered by proprietary assays and collaborative scientific support.
With 30 years of expertise, we deliver advanced compound screening for tubulin, myosin, sarcomere, kinesin, and small G-protein targets. Our mechanistically validated assays power early discovery, SAR-driven lead optimization, and robust preclinical profiling. Top pharma partners trust our CRO precision to accelerate pipeline decisions with reproducible, high-impact data.
Cytoskeleton partners closely with your team to deliver compound screens, leveraging deep expertise in cytoskeletal biology, protein biochemistry, and assay design. Our high-quality data supports key project decisions, while our focus on collaboration and reliability keeps leading pharma and biotech companies returning year after year.
Available services | Example target protein | Available assays | Target-associated diseases |
|---|---|---|---|
Porcine brain tubulin |
| Cancer | |
KIF18A | Microtubule-activated ATPase | Cancer | |
Cardiac myosin S1 fragment |
| Cardiomyopathies | |
SOS1 | Fluorescent GEF assay | Cancer | |
P50RhoGAP | Colorimetric GAP assay | Cancer | |
S. aureus FtsZ |
| Bacterial infection |
A Fortune 500 biopharmaceutical company required a comprehensive off-target counter-screen to evaluate the specificity of anti-kinesin drug candidates targeting KIF18A.
Four compounds plus control inhibitors were tested in a motor panel consisting of KIF2, KIF3C, KIFC3, KIF4A, KIF10(CENPE), KIF11(Eg5), KIF20A, and KIF23. IC50s confirmed that the compounds were highly specific to KIF18A and its close homologs KIF18B and KIF19A.
Some of the data generated by Cyto was included in a reported by Amgen Research company (CA, USA) and Broad Institute (MA, USA) in 2024 (Payton M. et al. Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers. Nature Cancer. 5, 66-84 (2024): Extended data Fig 2).
We proudly support leading research teams across pharma, biotech, and academia. Our custom services have helped advance discovery and preclinical programs in oncology, neuroscience, cardiology, and beyond.